Cynosure set to acquire Palomar Medical Technologies

Aesthetic laser makers Cynosure (NASDAQ: CYNO; Westford, MA) and Palomar Medical Technologies (NASDAQ: PMTI; Burlington, MA) have signed a definitive agreement in which Cynosure will acquire Palomar. The transaction is valued at approximately $294 million.

Michael Davin, Cynosure's chairman and CEO, notes that the acquistion creates new cross-selling opportunities and adds more than 40 patents to the company's portfolio.

The two companies have a total combined installed base of more than 20,000 aesthetic laser systems worldwide, with a distribution network that spans over 100 countries. Combined revenue in calendar year 2012 was more than $234 million, with 52% of product revenue coming from North America and 48% originating from international markets.

The transaction is subject to customary closing conditions, including the two companies' shareholder approval and regulatory approvals. Upon completion, Cynosure shareholders will own approximately 77% and Palomar shareholders will own approximately 23% of the combined company.

Davin will continue to serve as chairman and CEO; Timothy Baker will continue as executive vice president and CFO, adding a role as COO; and Joseph P. Caruso, Palomar's CEO, will serve as president and join the Board of Directors as vice chairman.

The company plans to relocate to Palomar's owned facility in Burlington, which is 15 miles south of Westford.


Follow us on Twitter, 'like' us on Facebook, and join our group on LinkedIn

Subscribe now to BioOptics World magazine; it's free!

Get All the BioOptics World News Delivered to Your Inbox

Subscribe to BioOptics World Magazine or email newsletter today at no cost and receive the latest news and information.

 Subscribe Now
Related Articles

Nipro Corporation set to commercialize Infraredx multimodal imaging system in Japan

Nipro Corporation, which is the exclusive distributor of Infraredx's TVC Imaging System, has established a manufacturing subsidiary to produce the system commercially.

LED Medical Diagnostics, BC Cancer Agency, and Genome BC sign agreement to develop oral cancer test

LED Medical Diagnostics has signed an agreement with the BC Cancer Agency and, in turn, Genome British Columbia (Genome BC) to create and commercialize a progression-risk assessment test for oral c...

Michelson Diagnostics closes $3.25 million financing round

Optical coherence tomography (OCT) medical device maker Michelson Diagnostics has closed its Series A2 financing round, raising $3.25 million (£1.98 million) from existing investors.

Carl Zeiss Meditec acquires Aaren Scientific, expanding intraocular lens portfolio

Carl Zeiss Meditec has acquired intraocular (IOL) lens maker Aaren Scientific, thereby expanding its IOL portfolio for ophthalmic surgeons.


Neuro15 exhibitors meet exacting demands: Part 2

Increasingly, neuroscientists are working with researchers in disciplines such as chemistry and p...

Why be free?

A successful career contributed to keeping OpticalRayTracer—an optical design software program—fr...

LASER Munich 2015 is bio-bent

LASER World of Photonics 2015 included the European Conferences on Biomedical Optics among its si...

White Papers

Understanding Optical Filters

Optical filters can be used to attenuate or enhance an image, transmit or reflect specific wavele...

How can I find the right digital camera for my microscopy application?

Nowadays, image processing is found in a wide range of optical microscopy applications. Examples ...



Twitter- BioOptics World

Copyright © 2007-2016. PennWell Corporation, Tulsa, OK. All Rights Reserved.PRIVACY POLICY | TERMS AND CONDITIONS